CN105188373B - 抑制“干扰素基因刺激蛋白”依赖性信号传导的组合物和方法 - Google Patents
抑制“干扰素基因刺激蛋白”依赖性信号传导的组合物和方法 Download PDFInfo
- Publication number
- CN105188373B CN105188373B CN201480024389.1A CN201480024389A CN105188373B CN 105188373 B CN105188373 B CN 105188373B CN 201480024389 A CN201480024389 A CN 201480024389A CN 105188373 B CN105188373 B CN 105188373B
- Authority
- CN
- China
- Prior art keywords
- propargyl
- days
- sting
- group
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361825009P | 2013-05-18 | 2013-05-18 | |
| US61/825,009 | 2013-05-18 | ||
| PCT/US2014/038526 WO2014189806A1 (en) | 2013-05-18 | 2014-05-18 | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105188373A CN105188373A (zh) | 2015-12-23 |
| CN105188373B true CN105188373B (zh) | 2017-09-22 |
Family
ID=51934007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480024389.1A Expired - Fee Related CN105188373B (zh) | 2013-05-18 | 2014-05-18 | 抑制“干扰素基因刺激蛋白”依赖性信号传导的组合物和方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US9549944B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2996472B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6400082B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105188373B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014189806A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2858722B8 (en) | 2012-06-08 | 2018-02-21 | Aduro BioTech, Inc. | Compostions and methods for cancer immunotherapy |
| SG11201502796RA (en) | 2012-12-13 | 2015-05-28 | Aduro Biotech Inc | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| JP2016506408A (ja) | 2012-12-19 | 2016-03-03 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 哺乳動物の環状ジヌクレオチドシグナル伝達経路の薬学的標的化 |
| JP2016524593A (ja) | 2013-04-29 | 2016-08-18 | メモリアル スローン−ケタリング キャンサー センター | セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法 |
| CN105377867B (zh) * | 2013-05-03 | 2019-11-12 | 加利福尼亚大学董事会 | I型干扰素的环状二核苷酸诱导 |
| CU24377B1 (es) | 2013-05-18 | 2018-12-05 | Aduro Biotech Inc | Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting |
| EP2996472B1 (en) | 2013-05-18 | 2019-03-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
| US10176292B2 (en) | 2013-07-31 | 2019-01-08 | Memorial Sloan-Kettering Cancer Center | STING crystals and modulators |
| EP3152217B1 (en) | 2014-06-04 | 2018-08-01 | GlaxoSmithKline Intellectual Property Development Limited | Cyclic di-nucleotides as modulators of sting |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| SG11201702401RA (en) | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2016130616A1 (en) | 2015-02-11 | 2016-08-18 | The Johns Hopkins University | Bacteria over-expressing c-di-amp and therapeutic methods |
| TWI706958B (zh) | 2015-03-10 | 2020-10-11 | 美商艾杜諾生物科技公司 | 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法 |
| US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| US20180340025A1 (en) | 2015-07-29 | 2018-11-29 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| CN108137641B (zh) | 2015-08-13 | 2022-04-01 | 默沙东公司 | 作为sting激动剂的环状双核苷酸化合物 |
| CN105367617A (zh) * | 2015-09-25 | 2016-03-02 | 武汉品生科技有限公司 | 一种基于环二腺核苷酸的衍生物、tat多肽及其在一型干扰素小分子中抑制剂的应用 |
| JP6411676B2 (ja) | 2015-12-03 | 2018-10-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Stingの調節因子としての環状プリンジヌクレオチド |
| CN106554416B (zh) * | 2015-12-09 | 2019-03-15 | 聊城市奥润生物医药科技有限公司 | 一种抗pd-l1人源化单克隆抗体联合干扰素基因刺激蛋白(sting)激动剂在抗肿瘤中的应用 |
| US20180369268A1 (en) * | 2015-12-16 | 2018-12-27 | Aduro Biotech, Inc. | Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production |
| CN108495651A (zh) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
| SMT202500412T1 (it) | 2016-01-11 | 2025-11-10 | Innate Tumor Immunity Inc | Dinucleotidi ciclici per il trattamento di condizioni associate all’attività di sting quali il cancro |
| JP6993699B2 (ja) | 2016-01-11 | 2022-02-03 | ウニヴェルズィテート・ツューリヒ | ヒトインターロイキン-2に対する免疫刺激性ヒト化モノクローナル抗体及びその融合タンパク質 |
| US20170239283A1 (en) * | 2016-02-23 | 2017-08-24 | Providence Health & Services - Oregon | Use of sting agonists to treat virally-induced and pre-malignant growths |
| IL280430B2 (en) * | 2016-03-18 | 2023-11-01 | Univ Texas | Cyclic dinucleotide compounds and methods of use |
| SG10201900628RA (en) | 2016-04-07 | 2019-02-27 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
| WO2017175156A1 (en) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| WO2017186711A1 (en) | 2016-04-25 | 2017-11-02 | Invivogen | Novel complexes of immunostimulatory compounds, and uses thereof |
| US10696985B1 (en) | 2016-06-06 | 2020-06-30 | Vanderbilt University | Reversibly crosslinked endosomolytic polymer vesicles for cytosolic drug delivery |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| DE102016113714A1 (de) | 2016-07-26 | 2018-02-01 | Rosa Karl | Transfektionsverfahren mit nicht-viralen Genliefersystemen |
| JP6636673B2 (ja) | 2016-10-04 | 2020-01-29 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | STINGアゴニストとしてのベンゾ[b]チオフェン化合物 |
| JOP20170188A1 (ar) * | 2016-11-25 | 2019-01-30 | Janssen Biotech Inc | ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting) |
| WO2018100558A2 (en) | 2016-12-01 | 2018-06-07 | Takeda Pharmaceutical Company Limited | Cyclic dinucleotide |
| RU2019122598A (ru) * | 2016-12-20 | 2021-01-22 | Мерк Шарп И Доум Корп. | Циклические динуклеотидные агонисты sting для лечения рака |
| ES2891326T3 (es) | 2017-01-27 | 2022-01-27 | Janssen Biotech Inc | Dinucleótidos cíclicos como agonistas de la STING |
| ES2924186T3 (es) * | 2017-01-27 | 2022-10-05 | Janssen Biotech Inc | Dinucleótidos cíclicos como agonistas de STING |
| MX2019009070A (es) | 2017-02-01 | 2019-10-30 | Modernatx Inc | Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion. |
| US20200055883A1 (en) | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
| JP2018131427A (ja) * | 2017-02-17 | 2018-08-23 | 国立研究開発法人理化学研究所 | 免疫細胞の制御技術 |
| CA3053568A1 (en) | 2017-02-21 | 2018-08-30 | Board Of Regents, The University Of Texas System | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling |
| US11466047B2 (en) | 2017-05-12 | 2022-10-11 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| MX2019015885A (es) | 2017-06-22 | 2020-09-10 | Novartis Ag | Moleculas de anticuerpo que se unen a cd73 y usos de las mismas. |
| US20200172628A1 (en) | 2017-06-22 | 2020-06-04 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| AU2018311965A1 (en) | 2017-08-04 | 2020-02-13 | Merck Sharp & Dohme Llc | Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment |
| MA49772A (fr) | 2017-08-04 | 2021-04-21 | Merck Sharp & Dohme | Agonistes benzo[b]thiophène de sting pour le traitement du cancer |
| US10526364B2 (en) * | 2017-08-15 | 2020-01-07 | Kumar Rajappan | Immune modulatory compositions |
| TWI808092B (zh) | 2017-08-30 | 2023-07-11 | 中國大陸商北京軒義醫藥科技有限公司 | 作為干擾素基因調節劑之刺激劑的環狀二核苷酸 |
| JP7208225B2 (ja) * | 2017-08-31 | 2023-01-18 | ブリストル-マイヤーズ スクイブ カンパニー | 抗癌剤としての環状ジヌクレオチド |
| US10947263B2 (en) * | 2017-08-31 | 2021-03-16 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| EP3675859A4 (en) | 2017-08-31 | 2021-06-30 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES |
| AU2018344902B2 (en) | 2017-10-05 | 2021-06-03 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) useful in treating HIV |
| US11377440B2 (en) | 2017-10-05 | 2022-07-05 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) |
| ES2997757T3 (en) * | 2017-10-16 | 2025-02-18 | Bristol Myers Squibb Co | Cyclic dinucleotides as anticancer agents |
| CN109694397B (zh) * | 2017-10-23 | 2021-08-31 | 上海弘翊生物科技有限公司 | 环状二核苷酸化合物、其制备方法和应用 |
| WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| WO2019081983A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | CD32B TARGETING ANTIBODIES AND METHODS OF USE |
| PH12020550585A1 (en) | 2017-11-10 | 2021-04-19 | Takeda Pharmaceuticals Co | Sting modulator compounds, and methods of making and using |
| JP7037667B2 (ja) | 2017-12-20 | 2022-03-16 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. | Stingアダプタータンパク質を活性化するホスホン酸結合を有する3’3’環状ジヌクレオチド |
| WO2019125974A1 (en) | 2017-12-20 | 2019-06-27 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| TW202003032A (zh) | 2018-03-23 | 2020-01-16 | 美商科迪亞克生物科學公司 | 包含s t i n g 促效劑之胞外囊泡 |
| US11702430B2 (en) | 2018-04-03 | 2023-07-18 | Merck Sharp & Dohme Llc | Aza-benzothiophene compounds as STING agonists |
| US10793557B2 (en) | 2018-04-03 | 2020-10-06 | Merck Sharp & Dohme Corp. | Sting agonist compounds |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| US12251394B2 (en) | 2018-06-01 | 2025-03-18 | Eisai R&D Management Co., Ltd. | Methods for the treatment of bladder cancer |
| US20210164992A1 (en) * | 2018-07-23 | 2021-06-03 | New York University | Compositions and methods related to innate response to dna and regulation of interferon-beta |
| KR102783784B1 (ko) | 2018-08-16 | 2025-03-21 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 화합물의 염 및 이의 결정 |
| WO2020041720A1 (en) | 2018-08-24 | 2020-02-27 | Codiak Biosciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
| CN118846110A (zh) | 2018-09-06 | 2024-10-29 | 第一三共株式会社 | 抗体药物偶联物 |
| SG11202101980VA (en) | 2018-09-12 | 2021-03-30 | Silverback Therapeutics Inc | Methods and composition for the treatment of disease with immune stimulatory conjugates |
| MA53659A (fr) | 2018-09-21 | 2022-02-23 | Shanghai De Novo Pharmatech Co Ltd | Analogue dinucléotidique cyclique, composition pharmaceutique associée et utilisation |
| US12508233B2 (en) | 2018-10-30 | 2025-12-30 | Vanderbilt University | Graft copolymers, methods of forming graft copolymers, and methods of use thereof |
| EP3883651A1 (en) * | 2018-11-19 | 2021-09-29 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| CN113574063B (zh) | 2019-03-07 | 2025-03-18 | 捷克共和国有机化学与生物化学研究所 | 3’3’-环二核苷酸及其前药 |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| WO2020178769A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020191361A2 (en) | 2019-03-21 | 2020-09-24 | Codiak Biosciences, Inc. | Extracellular vesicles for vaccine delivery |
| KR20210141554A (ko) | 2019-03-21 | 2021-11-23 | 코디악 바이오사이언시즈, 인크. | 세포외 소포 접합체 및 이의 용도 |
| US12281109B2 (en) | 2019-04-04 | 2025-04-22 | Merck Sharp & Dohme Llc | Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes |
| TW202104214A (zh) | 2019-04-05 | 2021-02-01 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 化合物 |
| CN114127082A (zh) * | 2019-05-09 | 2022-03-01 | 阿里戈斯治疗公司 | 作为sting调节剂的经修饰的环状二核苷化合物 |
| TWI925817B (zh) | 2019-05-10 | 2026-05-21 | 日商武田藥品工業股份有限公司 | 抗體藥物結合物 |
| US20220251200A1 (en) | 2019-07-03 | 2022-08-11 | Codiak Biosciences, Inc. | Extracellular vesicles targeting t cells and uses thereof |
| WO2021007160A1 (en) | 2019-07-05 | 2021-01-14 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| EP4003325A1 (en) | 2019-07-24 | 2022-06-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Inhibitors of the sting pathway for the treatment of hidradenitis suppurativa |
| KR20220056176A (ko) | 2019-08-02 | 2022-05-04 | 메르사나 테라퓨틱스, 인코포레이티드 | 암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물 |
| WO2021041532A1 (en) | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
| US20230103726A1 (en) | 2019-09-25 | 2023-04-06 | Codiak Biosciences, Inc. | Methods of producing extracellular vesicles |
| EP4034247A1 (en) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Sting agonist comprising exosomes for treating neuroimmunological disorders |
| CN114727947A (zh) | 2019-09-25 | 2022-07-08 | 科迪亚克生物科学公司 | 细胞外囊泡组合物 |
| JP2022551420A (ja) | 2019-09-25 | 2022-12-09 | コディアック バイオサイエンシーズ, インコーポレイテッド | 腫瘍を治療するためのil-12提示エクソソームとstingアゴニスト含有エクソソームとの併用 |
| WO2021067644A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| US20230074558A1 (en) | 2019-12-06 | 2023-03-09 | Mersana Therapeutics, Inc. | Dimeric compounds as sting agonists |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| US12678512B2 (en) | 2020-03-06 | 2026-07-14 | Daiichi Sankyo Company, Limited | Anti-EGFR antibody-drug conjugate with a cyclic dinucleotide derivative |
| WO2021184017A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Extracellular vesicles for treating neurological disorders |
| JP2023518414A (ja) | 2020-03-20 | 2023-05-01 | コディアック バイオサイエンシーズ, インコーポレイテッド | 治療のための細胞外小胞 |
| CN116196435B (zh) | 2020-04-02 | 2025-12-02 | 梅尔莎纳医疗公司 | 包含sting激动剂的抗体药物缀合物 |
| US20230141284A1 (en) | 2020-04-10 | 2023-05-11 | Ono Pharmaceutical Co., Ltd. | Cancer therapeutic method |
| EP4149457A1 (en) | 2020-05-15 | 2023-03-22 | Immunesensor Therapeutics, Inc. | Sting agonist combination treatments with immune checkpoint inhibitors |
| WO2021237100A1 (en) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
| KR20230047361A (ko) | 2020-07-01 | 2023-04-07 | 아르스 파마슈티컬스 인크. | 항-asgr1 항체 접합체 및 이의 용도 |
| JP2023537066A (ja) | 2020-08-07 | 2023-08-30 | タンボ・インコーポレイテッド | トランス-シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用 |
| EP4209506A4 (en) | 2020-09-02 | 2024-10-09 | Daiichi Sankyo Company, Limited | NEW ENDO-N-ACETYL GLUCOSAMINIDASE |
| WO2022066898A2 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Methods of producing extracellular vesicles |
| WO2022066883A1 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Extracellular vesicles comprising kras antigens and uses thereof |
| WO2022079175A1 (en) | 2020-10-14 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist |
| JP7875196B2 (ja) * | 2020-10-20 | 2026-06-17 | タイリガンド バイオサイエンス(シャンハイ)リミテッド | 多機能環状ジヌクレオチド及びその使用 |
| JP7397996B2 (ja) | 2020-11-09 | 2023-12-13 | 武田薬品工業株式会社 | 抗体薬物コンジュゲート |
| TW202241454A (zh) | 2021-02-01 | 2022-11-01 | 日商第一三共股份有限公司 | 抗體-免疫賦活化劑共軛物之新穎製造方法 |
| JP2024514707A (ja) | 2021-04-20 | 2024-04-02 | アンスティテュ・クリー | 免疫療法における使用のための組成物及び方法 |
| JP2024517131A (ja) | 2021-04-20 | 2024-04-19 | アンスティテュ・クリー | 免疫療法における使用のための組成物及び方法 |
| US20230121320A1 (en) | 2021-07-23 | 2023-04-20 | Immunesensor Therapeutics, Inc. | Sting agonist combination treatments with cytokines |
| WO2023056468A1 (en) | 2021-09-30 | 2023-04-06 | Codiak Biosciences, Inc. | Extracellular vesicle comprising cholesterol tagged sting-agonist |
| WO2023154799A1 (en) | 2022-02-14 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination immunotherapy for treating cancer |
| IL315341A (en) | 2022-03-02 | 2024-10-01 | Daiichi Sankyo Co Ltd | METHOD FOR PRODUCING Fc-CONTAINING MOLECULE |
| KR20250054799A (ko) | 2022-08-29 | 2025-04-23 | 다이이찌 산쿄 가부시키가이샤 | 변이 Fc 영역을 포함하는 항체 약물 콘쥬게이트 |
| GB202304385D0 (en) | 2023-03-24 | 2023-05-10 | Prostate Cancer Res | Combinatorial IL-15 therapy |
| CN116253766B (zh) * | 2023-03-27 | 2024-08-27 | 瑞阳(上海)新药研发有限公司 | 一种环二核苷酸2’,3’-cGAMP的制备方法 |
| WO2025262266A1 (en) | 2024-06-21 | 2025-12-26 | Institut National de la Santé et de la Recherche Médicale | Methods of determining the clinical phenotype of patients suffering from hidradenitis suppurativa |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005039535A1 (en) * | 2003-10-24 | 2005-05-06 | Alza Corporation | Preparation of lipid particles |
| US20080286296A1 (en) * | 2005-11-08 | 2008-11-20 | Thomas Ebensen | Cyclic-Dinucleotides and Its Conjugates as Adjuvants and Their Uses in Pharmaceutical Compositions |
| WO2011003025A1 (en) * | 2009-07-01 | 2011-01-06 | Rutgers, The State University Of New Jersey | Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof |
| US20120164107A1 (en) * | 2010-12-15 | 2012-06-28 | Portnoy Daniel A | Cyclic di-amp induction of type i interferon |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9110808D0 (en) | 1991-05-17 | 1991-07-10 | Retroscreen Ltd | Aids vaccine and method for its production |
| GB2257704B (en) | 1991-07-18 | 1995-03-01 | Erba Carlo Spa | Cyclic oligonucleotides phosphorothioates |
| US5904920A (en) | 1991-10-04 | 1999-05-18 | Whitehead Institute For Biomedical Research | Regulation of systemic immune responses utilizing cytokines and antigens |
| US5637483A (en) | 1991-10-04 | 1997-06-10 | Whitehead Institute For Biomedical Research | Irradiated tumor cell vaccine engineered to express GM-CSF |
| IT1262895B (it) | 1992-03-02 | 1996-07-22 | Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico. | |
| US5635160A (en) | 1995-06-07 | 1997-06-03 | The University Of North Carolina At Chapel Hill | Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions |
| US6033674A (en) | 1995-12-28 | 2000-03-07 | Johns Hopkins University School Of Medicine | Method of treating cancer with a tumor cell line having modified cytokine expression |
| US6277368B1 (en) | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
| ATE264911T1 (de) | 1998-02-02 | 2004-05-15 | Univ Johns Hopkins Med | Eine universelle immunmodulatorische cytokin- expressierende zelllinie in wartestelling. entsprechende zusammensetzungen und methoden ihrer herstellung und verwendungen |
| ID29546A (id) | 1999-02-15 | 2001-09-06 | Nippon Shinyaku Co Ltd | Polinukleotida dengan rantai yang diperpendek dan metode pembuatannya |
| US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
| CA2460014A1 (en) | 2000-09-21 | 2002-03-28 | The Regents Of The University Of California | Spas-1 cancer antigen |
| US7279883B2 (en) | 2001-01-23 | 2007-10-09 | Lydia L. Sohn | Particle analyzer and methods for use thereof |
| TW200303759A (en) | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
| AR040996A1 (es) * | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
| JP2007500697A (ja) * | 2003-07-28 | 2007-01-18 | デイビッド・ケイ・アール・カラオリス | 微生物病原体の毒性を減弱させる方法、および微生物のバイオフィルム形成を阻害する方法 |
| KR20060130038A (ko) | 2003-10-15 | 2006-12-18 | 메디뮨 인코포레이티드 | 리스테리아에 의거한 EphA2 백신 |
| US7592326B2 (en) | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
| WO2005089777A1 (en) | 2004-03-15 | 2005-09-29 | Karaolis David K R | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
| WO2006124340A2 (en) | 2005-05-06 | 2006-11-23 | The Regents Of California University | Microfluidic system for identifying or sizing individual particles passing through a channel |
| US20070059683A1 (en) | 2005-09-15 | 2007-03-15 | Tom Barber | Veterinary diagnostic system |
| WO2008030887A2 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Methods for designing parp inhibitors and uses thereof |
| EP2324044A4 (en) | 2008-08-04 | 2012-04-25 | Univ Miami | STING (STIMULATOR OF INTERFERON GENES) AS A REGULATOR OF BORROWING IMMUNE REACTIONS |
| US8840881B2 (en) | 2008-08-28 | 2014-09-23 | Aduro Gvax Inc. | Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer |
| KR101329374B1 (ko) | 2008-12-09 | 2013-11-14 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 면역자극성 올리고뉴클레오타이드 |
| CA2754896C (en) | 2009-03-09 | 2017-11-28 | Molecular Express, Inc. | Methods and compositions for liposomal formulation of antigens and uses thereof |
| CA2764374C (en) | 2009-06-05 | 2019-11-19 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
| US8771933B2 (en) | 2009-10-06 | 2014-07-08 | Massachusetts Institute Of Technology | Continuous-flow deformability-based cell separation |
| US20110289043A1 (en) | 2010-03-22 | 2011-11-24 | Brown University Research Foundation | Computational methods and compositions |
| CA2798074A1 (en) | 2010-04-27 | 2011-11-03 | The Johns Hopkins University | Immunogenic compositions and methods for treating neoplasia |
| US8450293B2 (en) | 2010-08-10 | 2013-05-28 | Rutgers, The State University Of New Jersey | Synthesis and characterization of C8 analogs of c-di-GMP |
| DK2640842T3 (en) | 2010-11-17 | 2018-08-13 | Aduro Biotech Inc | Methods and compositions for inducing an immune response to EGFRVIII |
| US8772474B2 (en) | 2010-12-22 | 2014-07-08 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
| AU2012243396A1 (en) | 2011-04-15 | 2013-10-31 | The University Of British Columbia | Method and apparatus for separation of particles |
| WO2013086331A1 (en) | 2011-12-07 | 2013-06-13 | President And Fellows Of Harvard College | High efficiency di-nucleotide cyclase |
| AU2013256468A1 (en) | 2012-04-30 | 2014-12-04 | Glen N. Barber | Modulating immune responses |
| EP2858722B8 (en) * | 2012-06-08 | 2018-02-21 | Aduro BioTech, Inc. | Compostions and methods for cancer immunotherapy |
| SG11201502796RA (en) * | 2012-12-13 | 2015-05-28 | Aduro Biotech Inc | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| JP2016506408A (ja) | 2012-12-19 | 2016-03-03 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 哺乳動物の環状ジヌクレオチドシグナル伝達経路の薬学的標的化 |
| JP2016524593A (ja) * | 2013-04-29 | 2016-08-18 | メモリアル スローン−ケタリング キャンサー センター | セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法 |
| CN105377867B (zh) | 2013-05-03 | 2019-11-12 | 加利福尼亚大学董事会 | I型干扰素的环状二核苷酸诱导 |
| EP2996472B1 (en) | 2013-05-18 | 2019-03-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
| CU24377B1 (es) | 2013-05-18 | 2018-12-05 | Aduro Biotech Inc | Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting |
| US10176292B2 (en) | 2013-07-31 | 2019-01-08 | Memorial Sloan-Kettering Cancer Center | STING crystals and modulators |
| AU2014340269B2 (en) | 2013-10-21 | 2018-06-21 | Drexel University | Use of STING agonists to treat chronic hepatitis B virus infection |
| JP2016538344A (ja) | 2013-11-19 | 2016-12-08 | ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago | 癌処置としてのstingアゴニストの使用 |
| EP3071229A4 (en) | 2013-11-22 | 2017-05-10 | Brock University | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants |
| US10421971B2 (en) | 2014-01-15 | 2019-09-24 | The University Of Chicago | Anti-tumor therapy |
| EP3152217B1 (en) | 2014-06-04 | 2018-08-01 | GlaxoSmithKline Intellectual Property Development Limited | Cyclic di-nucleotides as modulators of sting |
-
2014
- 2014-05-18 EP EP14800803.0A patent/EP2996472B1/en not_active Not-in-force
- 2014-05-18 WO PCT/US2014/038526 patent/WO2014189806A1/en not_active Ceased
- 2014-05-18 CN CN201480024389.1A patent/CN105188373B/zh not_active Expired - Fee Related
- 2014-05-18 JP JP2016514152A patent/JP6400082B2/ja not_active Expired - Fee Related
- 2014-05-19 US US14/280,668 patent/US9549944B2/en not_active Expired - Fee Related
-
2017
- 2017-01-20 US US15/411,850 patent/US10189873B2/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005039535A1 (en) * | 2003-10-24 | 2005-05-06 | Alza Corporation | Preparation of lipid particles |
| US20080286296A1 (en) * | 2005-11-08 | 2008-11-20 | Thomas Ebensen | Cyclic-Dinucleotides and Its Conjugates as Adjuvants and Their Uses in Pharmaceutical Compositions |
| WO2011003025A1 (en) * | 2009-07-01 | 2011-01-06 | Rutgers, The State University Of New Jersey | Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof |
| US20120164107A1 (en) * | 2010-12-15 | 2012-06-28 | Portnoy Daniel A | Cyclic di-amp induction of type i interferon |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105188373A (zh) | 2015-12-23 |
| US20170218008A1 (en) | 2017-08-03 |
| JP2016531842A (ja) | 2016-10-13 |
| EP2996472A1 (en) | 2016-03-23 |
| US20140341976A1 (en) | 2014-11-20 |
| JP6400082B2 (ja) | 2018-10-03 |
| WO2014189806A1 (en) | 2014-11-27 |
| EP2996472B1 (en) | 2019-03-27 |
| HK1217606A1 (zh) | 2017-01-20 |
| US10189873B2 (en) | 2019-01-29 |
| EP2996472A4 (en) | 2016-12-28 |
| US9549944B2 (en) | 2017-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10189873B2 (en) | Compositions and methods for inhibiting “stimulator of interferon gene”-dependent signalling | |
| JP6704012B2 (ja) | 明確な立体化学を有する環状プリンジヌクレオチドを含む組成物ならびにそれらの調製および使用方法 | |
| JP6453855B2 (ja) | 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を活性化するための組成物及び方法 | |
| AU2013287630B2 (en) | Chiral nucleic acid adjuvant | |
| US10149905B2 (en) | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent | |
| ES2456964T3 (es) | Conjugados de agonistas de TLR sintéticos y usos de los mismos | |
| HK1247089A1 (zh) | 用於活化“干扰素基因刺激物”依赖性信号传导的组合物和方法 | |
| KR20130056249A (ko) | 인지질 약물 유사체 | |
| KR20150022996A (ko) | 암 면역요법을 위한 조성물 및 방법 | |
| KR20220150356A (ko) | 치료제 및 이의 접합체 | |
| US12295970B2 (en) | Imidazoquinoline compounds and prodrugs thereof | |
| HK1217606B (en) | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling | |
| HK1219024B (en) | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling | |
| HK1212707B (en) | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use | |
| BRPI0807196B1 (pt) | Compostos 6-amino-8-hidróxipurin-9-ilbenzil substituídos, e, usos dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1217606 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1217606 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170922 Termination date: 20210518 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |